Broncovaleas ® - Salbutamol

Broncovaleas ® is a drug based on Salbutamol sulfate

THERAPEUTIC GROUP: Adrenergics for aerosols and other drugs for obstructive airway syndromes

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications Broncovaleas ® - Salbutamol

Broncovaleas ® is indicated in the treatment of bronchial asthma and obstructive bronchopathy with asthmatic component.

Mechanism of action Broncovaleas ® - Salbutamol

Salbutamol, active ingredient of Broncovaleas ®, is a sympathomimetic amine falling into the category of selective beta 2 adrenergic receptor agonists, characterized by a half-life estimated between 2 and 7 hours.

The main mechanism of action of the aforementioned active principle is carried out through the binding and activation of the Beta 2 adrenergic receptors expressed by the tracheobronchial musculature, with consequent increase of the cyclic AMP and relative bronchodilation.

Everything also appears to be supported by other mechanisms of action, not yet fully clarified, which associate a potential action stabilizing the mastocyte membrane with Salbutamol, which is effective in reducing the phenomenon of degranulation and release of vasoactive amines responsible for the classic allergic and asmatiform symptoms.

The amount of drug eventually absorbed is generally excreted via the urine in part unchanged partly conjugated to glucuronic acid.

Studies carried out and clinical efficacy

SALBUTAMOLO AS A PREACHER OF ASMATIC ATTACKS

Clin Exp Allergy. 2013 Oct; 43 (10): 1144-51. doi: 10.1111 / cea.12166.

Interesting study that associates the consumption frequency of Salbutamol with the risk of developing aggravation of the asthmatic condition, thus being able to use this value as a predictor of the risk of serious asthmatic attacks.

SALBUTAMOLO E IPRATROPIO BROMURO COMPARISON

Eur J Clin Pharmacol. 2012 Oct; 68 (10): 1375-83. doi: 10.1007 / s00228-012-1256-z. Epub 2012 Mar 29.

Study demonstrating that salbutamol is better than other drugs used for the treatment of asthma like Ipratropium bromide in preventing spirometric variations linked to gas exchange, probably associated with the improvement of other parameters such as the presence of exudate in the respiratory tract.

SALBUTAMOLO IN PEDIATRICS

Br J Nurs. 2012 Apr 26-May 9; 21 (8): S30-4.

Important revision, which seeks to standardize Salbutamol therapy, identifying an algorithm useful in intravenous administration of Salbutamol in children, so that everything can be carried out in the safest way possible.

Method of use and dosage

Broncovaleas ®

Pressurized suspension for inhalation from 100 mcg of Salbutamol for dispensing;

0.5% solution to be sprayed with Salbutamol;

Salbutamol 2 mg syrup per 5 ml of product.

The choice of the pharmaceutical format, the dosage to be used and the timing of intake is the responsibility of the doctor after having carefully assessed the patient's overall health and the severity of his clinical picture.

Generally in adults it is recommended to use 2 sprays 3-6 times a day, 5 drops to be sprayed in 2 ml of distilled water 3 times a day or 2-4 ml of syrup twice a day.

Warnings Broncovaleas ® - Salbutamol

Broncovaleas ® therapy must necessarily be preceded by a careful medical examination in order to clarify the clinical origin of the symptomatology and the possible prescription appropriateness of Salbutamol.

therapy with this drug should be carried out with particular caution in patients suffering from cardiovascular diseases, glaucoma, hyperthyroidism, pheochromocytoma, diabetes and prostatic hypertrophy, much more exposed to an aggravation of the present clinical picture.

Medical supervision during the entire treatment is necessary in order to ascertain its therapeutic efficacy and safety.

Broncovaleas ® contains among its excipients parahydroxybenzoates, potentially responsible for allergic reactions, including bronchospasm, and sucrose, generally contraindicated in patients with hereditary fructose intolerance, glucose-galactose malabsorption syndrome or sucrase-isomaltase enzyme deficiency.

The use of Broncovaleas ®, outside the medical prescriptions for which it is indicated, is prohibited in and out of the race.

It is recommended to keep the medicine out of the reach of children.

PREGNANCY AND BREASTFEEDING

The use of Broncovaleas ® during pregnancy and in the subsequent period of breastfeeding is generally not recommended during pregnancy and in the subsequent period of breastfeeding, due to the muscle relaxant action on the uterine muscles, and to the ability of Salbutamol to concentrate in breast milk. .

Interactions

The patient receiving Broncovaleas ® should avoid the simultaneous intake of non-selective Beta 2 agonist and beta blockers, as well as diuretics, steroids and xanthine derivatives, potentially responsible for hypokalemia.

Contraindications Broncovaleas ® - Salbutamol

The use of Broncovaleas ® is contraindicated in patients with hypersensitivity to the active ingredient or to one of its excipients, in patients suffering from severe cardiopathies, glaucoma, prostatic hypertrophy and urinary retention syndrome or intestinal obstruction:

Undesirable effects - Side effects

Broncovaleas ® therapy may expose the patient to the risk of hypokalemia, nervousness and restlessness, dizziness, headache and tremor, myalgia, muscle spasm, arrhythmia, palpitations and tachycardia. Inhalation may also cause throat irritation, dry mouth and paradoxical bronchospasm.

Although the onset of symptoms linked to hypersensitivity to the active ingredient has also been rarely documented.